Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
52.20
-0.20 (-0.38%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
64
65
Next >
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.
Via
Benzinga
Market Whales and Their Recent Bets on BMY Options
August 27, 2024
Via
Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
August 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
August 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Key Takeaways From Bristol-Myers Squibb Analyst Ratings
August 22, 2024
Via
Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
August 21, 2024
Via
Benzinga
Check Out What Whales Are Doing With BMY
August 16, 2024
Via
Benzinga
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
August 23, 2024
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and...
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Smart Money Is Betting Big In BMY Options
August 09, 2024
Via
Benzinga
Smart Money Is Betting Big In BMY Options
August 06, 2024
Via
Benzinga
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
August 20, 2024
With yields above 4%, these stocks could do a lot to boost your passive income stream
Via
The Motley Fool
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Where Will Bristol Myers Squibb Be in 5 Years?
August 18, 2024
The drugmaker will go through key changes by the end of the decade.
Via
The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
August 18, 2024
ETFs offer a good way to own a diversified portfolio of income-producing equities.
Via
The Motley Fool
Topics
ETFs
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
August 15, 2024
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
August 14, 2024
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction.
Via
Benzinga
Topics
Workforce
Exposures
Layoff
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...
Via
Benzinga
The 3 Best Healthcare Stocks to Buy in August 2024
August 12, 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Via
InvestorPlace
Bristol-Myers Squibb Co: Is It A Buy?
August 11, 2024
As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens:...
Via
Talk Markets
3 Stocks Retirees Should Absolutely Love
August 10, 2024
All of these stocks can provide steady income to retired investors.
Via
The Motley Fool
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.
Via
InvestorPlace
Exposures
Product Safety
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
August 05, 2024
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...
Via
Benzinga
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
August 05, 2024
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.
Via
The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
August 03, 2024
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
The 3 Biggest Earnings Beats for Q2 as of August 1, 2024
August 01, 2024
The stocks serving up the biggest earnings beats may just go on to offer investors fabulous returns going forward.
Via
InvestorPlace
Topics
Earnings
Exposures
Financial
8 Health Care Stocks With Whale Alerts In Today's Session
August 01, 2024
Via
Benzinga
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
August 01, 2024
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment.
Via
InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
64
65
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.